Last reviewed · How we verify

Desyrel — Competitive Intelligence Brief

Desyrel (trazodone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SARI (Serotonin antagonist and reuptake inhibitor). Area: Neuroscience.

marketed SARI (Serotonin antagonist and reuptake inhibitor) HLA class I histocompatibility antigen, A-3 alpha chain, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Desyrel (trazodone) — Generic (originally Angelini/Pragmaten). Serotonin antagonist and reuptake inhibitor (SARI) that blocks 5-HT2A receptors and H1 receptors, used primarily as a sedative-hypnotic at low doses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Desyrel TARGET trazodone Generic (originally Angelini/Pragmaten) marketed SARI (Serotonin antagonist and reuptake inhibitor) HLA class I histocompatibility antigen, A-3 alpha chain, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A 1981-12-24

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SARI (Serotonin antagonist and reuptake inhibitor) class)

  1. Generic (originally Angelini/Pragmaten) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Desyrel — Competitive Intelligence Brief. https://druglandscape.com/ci/trazodone. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: